Getting fast track and breakthrough drug designations from FDA can be considered quite big accomplishments and wouldn’t have come easily. So there is definitely value that FDA can clearly see here. AT is usually chatty both on videos and announcements but not providing updates on the progress of the company’s first phase 3 trial can create doubt in SHs minds. Given this is a blinded trial we only have to wait till the very end as there have been no interim updates as well. Fingers crossed for positive results.
On the contrary, if the market continues to undervalue the company despite all their trials, pipelines and results thus far it can only be used as an accumulation opportunity.
No advice.
CU6 Price at posting:
$3.30 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)